Company news

Lantern Pharma Inc. news in 2023

Lantern Pharma Inc.'s news releases, calls and decks from 2023, newest first.

View company

FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL)

November 29, 2023

Lantern Pharma Reports Third Quarter 2023 Financial Results and Operational Highlights

November 7, 2023

Lantern Pharma to Report Third Quarter 2023 Operating & Financial Results on November 8th, 2023 at 4: 30 p.m. ET

October 31, 2023

Lantern Pharma to Present at the ThinkEquity Conference on October 19 at 1: 30 p.m. ET

October 9, 2023

Lantern Pharma Announces Publication in Clinical Cancer Research Highlighting the Enhanced Efficacy of LP-184 in Glioblastoma

October 2, 2023

Lantern Pharma Announces First Patient Dosed in the Phase 1 Study for LP-184 in Advanced Solid Tumors

September 24, 2023

Lantern Pharma Receives IND Clearance from FDA Enabling Phase 1 Initiation for Drug Candidate LP-284 in Non-Hodgkin’s Lymphomas

September 17, 2023

Lantern Pharma to Present Data Highlighting the Anti-Tumor Potency of Drug Candidate LP-284 in Non-Hodgkin’s Lymphomas at the Society of Hematologic Oncology Annual Meeting

August 30, 2023

Lantern Pharma Expands AI Capabilities of RADR® Platform to Accelerate the Clinical Development of Immune Checkpoint Inhibitors

August 27, 2023

Lantern Pharma Receives Notice of US Patent Allowance for Drug Candidate LP-184 for the Treatment of Rare Pediatric Brain Cancer, ATRT

August 13, 2023

Lantern Pharma Reports Second Quarter 2023 Financial Results and Operational Highlights

August 8, 2023

Lantern Pharma to Report Second Quarter 2023 Operating & Financial Results on August 9, 2023 at 4: 30 p.m. ET

August 1, 2023

Lantern Pharma to Participate and Present at Multiple Upcoming Conferences

July 16, 2023

Oncotarget Publishes New Data by Lantern Pharma, an AI Company Developing Cancer Therapies, Further Supporting Clinical Advancement of LP-284, a Novel Synthetically Lethal Drug Candidate for Non-Hodgkin’s Lymphomas

June 25, 2023

Lantern Pharma Receives FDA Clearance of IND Application for Drug Candidate LP-184 in Solid Tumors

June 11, 2023

Lantern Pharma Leverages AI Platform, RADR®, to Develop Breakthrough Antibody Drug Conjugates (ADCs) in Collaboration with Bielefeld University

June 7, 2023

Lantern Pharma to Present at the Lytham Partners Spring 2023 Investor Conference Thursday, May 18th at 9: 00 a.m. ET

May 16, 2023

Lantern Pharma Reports First Quarter 2023 Financial Results and Operational Highlights

May 8, 2023

Lantern Pharma Selects REPROCELL USA to Provide Support for the Phase 2 Harmonic™ Clinical Trial

May 2, 2023

Lantern Pharma to Report First Quarter 2023 Operating & Financial Results on May 9, 2023 at 4: 30 p.m. ET

May 1, 2023

Lantern Pharma Develops Top-Ranked AI Algorithms to Predict the Blood-Brain-Barrier Permeability of Any Compound

May 1, 2023

Lantern Pharma Receives Notice of Allowance for Composition of Matter Patent Covering Drug Candidate LP-284

April 12, 2023

Lantern Pharma Announces First Patient Dosed in the Phase 2 Study, Harmonic™, for LP-300 in Never Smokers with Advanced Non-Small Cell Lung Cancer

March 27, 2023

Lantern Pharma to Present at Upcoming Scientific Conferences and Webinars

March 20, 2023

Lantern Pharma Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Operational Highlights

March 19, 2023

Lantern Pharma to Present at the American Association for Cancer Research (AACR) Annual Meeting

March 14, 2023

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2022 Operating & Financial Results on March 20, 2023 at 4: 30 p.m. ET

March 12, 2023

Lantern Pharma Confirms It Had No Exposure to Silicon Valley Bank (SVB), Silvergate Bank, or Signature Bank

March 12, 2023

Lantern Pharma Announces New Data and Development Focus for LP-100 with PARP Inhibitors

March 8, 2023

Lantern Pharma to Host Virtual KOL Webinar on Synthetic Lethality, the Powerful Mechanism of Action Behind Several of Lantern’s Drug Candidates, Featuring Zoltan Szallasi, M.D.

March 7, 2023

Lantern Pharma Announces Formation of Starlight Therapeutics to Advance Transformative Therapies for CNS (Central Nervous System) and Brain Cancers

March 5, 2023

Lantern Pharma Expands Clinical Leadership Team to Further Advance its Ongoing and Upcoming Clinical Trials

March 1, 2023

Lantern Pharma and TTC Oncology Establish AI Collaboration to Expand the Clinical Development of Drug Candidate TTC-352

February 26, 2023

Lantern Pharma Further Enhances Capabilities of its AI Drug Discovery Platform, RADR®, with Product Development Roadmap for the Development of Antibody Drug Conjugates

February 14, 2023

Lantern Pharma Receives Pre-IND Feedback from the FDA, Clearing a Path for Drug Candidate LP-184’s Phase 1 Clinical Trial in Q2 2023

January 16, 2023

FDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in Mantle Cell Lymphoma

January 4, 2023

Calls in 2023

Decks in 2023